PH-3861 / Phio Pharma - LARVOL DELTA

Phio Pharmaceuticals Announces Two Upcoming Data Presentations at Scientific Conferences in October 2021 (PRNewswire) - "Phio Pharmaceuticals Corp...announced two poster presentations at upcoming scientific conferences scheduled to take place in October 2021. These presentations include an abstract being presented by the Phio team at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, which is being held from October 7-10, 2021; and a poster presentation of data from a study using INTASYL by the Company's collaborators at Helmholtz Zentrum München (HMGU) at the 8th Immunotherapy of Cancer Conference (ITOC8), which is being held from Oct. 8–9, 2021."

Clinical data • Oncology

[VIRTUAL] Dual targeting PD-1 and BRD4 with INTASYL self-delivering RNAi elicits persistent anti-tumor immunity in-vivo following complete resolution of tumors (ESMO 2021) - "These data show that, in addition to eliciting stable complete resolution, dual-targeting IT treatment with INTASYL PH-894/mPH-762 engenders durable systemic anti-tumor immunity and supports a planned clinical study to start later this year in France."

Preclinical • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor • BRD4 • PD-1

Phio Pharmaceuticals Presents Data at ESMO 2021 Demonstrating Persistent Anti-Tumor Immunity with INTASYL Dual-Targeting PD-1 and BRD4 (PRNewswire) - "The study was performed to show the synergistic activity of co-targeting PD-1 and BRD4 with one INTASYL formulation (PH-3861) in a preclinical in vivo hepatocellular carcinoma model. The results show that up to 83% of the animals treated with PH-3861 had a complete response when treated at low doses, namely doses suboptimal for monotherapy. Moreover, this treatment induced a durable and specific systemic anti-tumor immune response, without requiring further treatment."

Preclinical • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology

Phio Pharmaceuticals Announces Upcoming Data Presentation at the ESMO Virtual Congress 2021 (PRNewswire) - “Phio Pharmaceuticals Corp…announced that new data in support of upcoming clinical studies is scheduled to be presented at the European Society of Medical Oncology (ESMO) Virtual Congress 2021, which is being held from September 16-21, 2021.”

Preclinical • Oncology

[VIRTUAL] INTASYL self-delivering RNAi therapy specifically dual-targeting BRD4 and PD-1 to elicit complete tumor responses and evidence of synergy in a subcutaneous Hepa1-6 model of murine hepatoma in C57BL/6N mice. (ASCO 2021) - "Positive control groups received systemic (IP) (+)-JQ-1 (13.33mg/dose; qdx5), anti-mouse PD-1 antibody (75 µg; Days 1, 3, 7, 10, 14), or both treatments . These data demonstrate proof-of-concept of the therapeutic potential of rational dual-targeted INTASYL provided as single formulation in vivo, suggesting potential for meaningful clinical therapeutic impact."

Preclinical • Gastrointestinal Cancer • Hepatocellular Cancer • Immune Modulation • Inflammation • Liver Cancer • Oncology • Solid Tumor • BRD4 • PD-1

Phio Pharmaceuticals Presents New In Vivo Data at the 2021 ASCO Annual Meeting Showing Dual-Targeting INTASYL Offers Increased Efficacy and Safety Potential Over Other Therapeutic Approaches (PRNewswire) - “Phio Pharmaceuticals Corp…announced positive in vivo data that provide further evidence on the utility of its INTASYL™ self-delivering RNAi therapy platform in the field of immuno-oncology. The new study data show how INTASYL can be easily deployed to target multiple proteins and provide evidence of the synergy of the Company's pipeline products. In the study, INTASYL specifically dual-targeting BRD4 and PD-1 elicited complete tumor responses in an in vivo hepatoma model, and significantly outperformed the efficacy of small molecule and antibody treatments towards the same targets…in treating a subcutaneous Hepa1-6 model of murine hepatoma in C57BL/6N mice. Positive controls included JQ-1, a small molecule inhibitor of BRD4 and anti-mouse PD-1 monoclonal antibody (mAb) or both treatments.”

Preclinical • Oncology